Abcuro reports preclincal data showing that KLRG1 antibody blockade produced anticancer responses in breast cancer, colon cancer, and melanoma models, supporting KLRG1 as a promising new immuno-oncology target.

Labshares expands its advanced equipment offerings for cell sorting, protein analysis, and flow cytometry.

With occupancy nearing 90% across its existing facilities, Labshares is expanding to more than 100,000 square feet to meet demand for flexible, capital-efficient lab space that helps biotechs scale smarter and focus on science.